- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.08. | NYRADA INC.: Change in substantial holding - M Azzi | 1 | ASX | ||
| 24.08. | NYRADA INC.: Cleansing Statement | - | ASX | ||
| 24.08. | NYRADA INC.: Application for quotation of securities - NYR | - | ASX | ||
| 21.08. | Daily Special: Rural Funds Group, Nyrada, Liberty Metals, Noble Helium, Island Pharmaceuticals | 4 | Finance News Network | ||
| 21.08. | NYRADA INC.: Xolatryp Demonstrates Cardioprotection in Preclinical Study | - | ASX | ||
| 18.08. | NYRADA INC.: Annual Report for year ended 30 June 2026 | 1 | ASX | ||
| NYRADA INC Aktie jetzt für 0€ handeln | |||||
| 18.08. | NYRADA INC.: Nyrada Full Year Results FY2026 | 1 | ASX | ||
| 18.08. | NYRADA INC.: Preliminary Final Report | 2 | ASX | ||
| 18.08. | NYRADA INC.: Appendix 4G and Corporate Governance Statement | 1 | ASX | ||
| 05.08. | NYRADA INC.: Change in substantial holding - M Azzi | 1 | ASX | ||
| 05.08. | NYRADA INC.: CSANZ26 Conference Poster | 1 | ASX | ||
| 27.07. | NYRADA INC.: Quarterly Activities Report and Appendix 4C | - | ASX | ||
| 15.07. | NYRADA INC.: Response to ASX Price Query | - | ASX | ||
| 15.07. | NYRADA INC.: Change in substantial holding - M Azzi | - | ASX | ||
| 06.07. | NYRADA INC.: PROTECT-MI Phase IIa Clinical Trial Update No 2 | - | ASX | ||
| 30.06. | NYRADA INC.: Notification of cessation of securities - NYR | - | ASX | ||
| 30.06. | NYRADA INC.: Cleansing Statement | - | ASX | ||
| 30.06. | NYRADA INC.: Application for quotation of securities - NYR | - | ASX | ||
| 29.06. | NYRADA INC.: Cleansing Statement | - | ASX | ||
| 29.06. | NYRADA INC.: Application for quotation of securities - NYR | - | ASX |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOAFFINITY TECHNOLOGIES | 15,170 | -0,65 % | Morning Market Movers: Ultragenyx Pharmaceutical, bioAffinity Technologies, Tilly's, Inc., Snowflake See Big Swings | BEIJING (dpa-AFX) - At 7:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,600 | -0,03 % | Summit Therapeutics Stock Rises 11% | ||
| QIAGEN | 37,435 | -0,09 % | Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit | ||
| TARSUS PHARMACEUTICALS | 90,84 | +0,07 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen | |
| TYRA BIOSCIENCES | 28,650 | 0,00 % | Tyra Bio rises on upcoming mid-stage trial readout for bladder cancer drug | ||
| RECURSION PHARMACEUTICALS | 3,635 | +0,14 % | Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? | ||
| PRAXIS PRECISION MEDICINES | 352,42 | +0,17 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VIR BIOTECHNOLOGY | 11,385 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen | |
| VERA THERAPEUTICS | 35,890 | 0,00 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| MODERNA | 125,24 | -0,03 % | BioNTech Aktie: Nach dem Moderna-Rausch folgt der Kater | Bei der BioNTech Aktie ging es in den vergangenen Tagen wild zu. Erst schwamm das an der NASDAQ notierte Papier auf der Welle positiver Moderna-Nachrichten nach oben und fuhr hohe Gewinne ein, dann... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,270 | -0,04 % | Dyne to present preclinical data on four DMD therapies | ||
| RELAY THERAPEUTICS | 19,060 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 117,48 | +0,08 % | Can KT-621 Mark a Turning Point for Kymera Therapeutics? | ||
| ALUMIS | 11,090 | -0,09 % | Alumis-Aktie: No Brainer Club feiert zweistellige Kursgewinne zum Start | Gewohnt gutes Timing: Der No Brainer Club hat auch bei Alumis im richtigen Moment zugeschlagen und blickt bereits nach einem Tag auf zweistellige Kursgewinne. Nach dem massiven Abverkauf infolge enttäuschender... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 34,140 | +0,12 % | Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? |
NYRADA INC CDIS gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NYRADA INC CDIS finden Sie auf Wallstreet Online.